https://ideawaza.com/api.php?action=feedcontributions&feedformat=atom&user=80.5.48.43IdeaWazaWiki - User contributions [en]2026-10-05T14:47:20ZUser contributionsMediaWiki 1.46.0https://ideawaza.com/index.php?title=Medherant&diff=88903Medherant2020-12-11T09:14:31Z<p>80.5.48.43: </p>
<hr />
<div>{{Use dmy dates|date=October 2017}}<br />
{{Use British English|date=October 2017}}<br />
{{self-published|date=October 2016}}<br />
<br />
{{Infobox company<br />
| name = Medherant Ltd<br />
| logo = File:Medherant Ltd logo.png<br />
| type = [[Private Limited Company]]<br />
| industry = [[Pharmaceuticals]]<br />
| founded = 2015<br />
| founder = Professor David Haddleton<br />
| hq_location_city = Coventry<br />
| hq_location_country = United Kingdom<br />
| website = {{Official website |www.medherant.co.uk}}<br />
}}<br />
<br />
'''Medherant Ltd''' is a British [[pharmaceutical company]] currently based in [[Coventry]]. The company develops [[over-the-counter]] (OTC) and prescription [[transdermal patch]]es for [[drug delivery]].<br />
<br />
==History==<br />
Medherant Ltd was founded as a [[university spin-off]] by Professor David Haddleton and the [[University of Warwick]] in 2015 for the purpose of commercialisation of a novel drug delivery system.<br />
Started as a research project in Haddleton Group at the University of Warwick in 2013, the company operates at the [[University of Warwick Science Park]] since March 2015 after securing an investment from the [[Mercia Fund Management]] in 2014.<br />
<br />
==Research==<br />
Using its research in [[bioadhesive]]s and [[polymer chemistry]], the company intends to introduce patches in 2019 which are able to deliver drugs via the trans[[epidermal]] route.<ref>{{cite web |url=https://www2.warwick.ac.uk/newsandevents/pressreleases/researchers_create_world146s/ |title=Researchers create World’s first ibuprofen patch - delivering pain relief directly through skin |publisher=University of Warwick |accessdate=16 October 2016}}</ref> Medherant's TEPI patch technology aims to provide controlled delivery of the correct dose, and better patient experience. The technology is also designed to be environmentally and economically efficient, requiring no [[solvent]]s for the fabrication process.<ref>{{cite web |url=http://www.medherant.co.uk/about-us |title=Medherant is developing a first-in-class transdermal drug delivery patch for prescription and OTC medicines |publisher=Medherant Ltd |accessdate=16 October 2016}}</ref><br />
<br />
<br />
<br />
==References==<br />
{{reflist}}<br />
<br />
==External links==<br />
* [http://www.haddleton.org Haddleton Group]<br />
<br />
[[Category:Companies based in Coventry]]<br />
[[Category:Pharmaceutical companies of the United Kingdom]]</div>80.5.48.43https://ideawaza.com/index.php?title=Medherant&diff=88902Medherant2020-12-11T09:13:55Z<p>80.5.48.43: /* Research */</p>
<hr />
<div>{{Use dmy dates|date=October 2017}}<br />
{{Use British English|date=October 2017}}<br />
{{self-published|date=October 2016}}<br />
<br />
{{Infobox company<br />
| name = Medherant Ltd<br />
| logo = File:Medherant Ltd logo.png<br />
| type = [[Private Limited Company]]<br />
| industry = [[Pharmaceuticals]]<br />
| founded = 2015<br />
| founder = Professor David Haddleton<br />
| hq_location_city = Coventry<br />
| hq_location_country = United Kingdom<br />
| website = {{Official website |www.medherant.co.uk}}<br />
}}<br />
<br />
'''Medherant Ltd''' is a British [[pharmaceutical company]] currently based in [[Coventry]]. The company develops [[over-the-counter]] (OTC) and prescription [[transdermal patch]]es for [[drug delivery]].<br />
<br />
==History==<br />
Medherant Ltd was founded as a [[university spin-off]] by Professor David Haddleton and the [[University of Warwick]] in 2015 for the purpose of commercialisation of a novel drug delivery system.<br />
Started as a research project in Haddleton Group at the University of Warwick in 2013, the company operates at the [[University of Warwick Science Park]] since March 2015 after securing an investment from the [[Mercia Fund Management]] in 2014.<br />
<br />
==Research==<br />
Using its research in [[bioadhesive]]s and [[polymer chemistry]], the company intends to introduce patches in 2019 which are able to deliver drugs via the trans[[epidermal]] route.<ref>{{cite web |url=https://www2.warwick.ac.uk/newsandevents/pressreleases/researchers_create_world146s/ |title=Researchers create World’s first ibuprofen patch - delivering pain relief directly through skin |publisher=University of Warwick |accessdate=16 October 2016}}</ref> Medherant's TEPI patch technology aims to provide controlled delivery of the correct dose, and better patient experience. The technology is also designed to be environmentally and economically efficient, requiring no [[solvent]]s for the fabrication process.<ref>{{cite web |url=http://www.medherant.co.uk/about-us |title=Medherant is developing a first-in-class transdermal drug delivery patch for prescription and OTC medicines |publisher=Medherant Ltd |accessdate=16 October 2016}}</ref><br />
<br />
M<br />
<br />
==References==<br />
{{reflist}}<br />
<br />
==External links==<br />
* [http://www.haddleton.org Haddleton Group]<br />
<br />
[[Category:Companies based in Coventry]]<br />
[[Category:Pharmaceutical companies of the United Kingdom]]</div>80.5.48.43